Surya Singh, MD, Explains How Drug Procurement Affects Cost and Access
Surya Singh, MD, discussed dynamics that affect biosimilar uptake on the medical benefits side and how that differs from the pharmacy benefits side at the recent FDA/Federal Trade Commission workshop on anticompetitive practices.
Surya Singh, MD, is the president of Singh Healthcare Advisors
Transcript:
What are some of the dynamics that affect biosimilar uptake on the medical benefits side versus the pharmacy benefits side?
On the pharmacy benefit side, just to start there, the formulary concept and preferred drug concepts are critical to user uptake. So, getting that contract to become the preferred product, which in today's market is really around achieving the lowest net cost, is really critical. And that's done on a really large scale through a few entities, [which] do a lot of the procurement on the pharmacy benefit side; whereas, on the medical benefits side, individual health systems, academic medical centers, for instance, and then large multidisciplinary practices or specialty specific practices do their own procurement. So, the splintering of the market is much greater, and providers have to think about what would be the best, really, largely from an economic perspective, so [what would be the] lowest cost for them to inventory and then use across all of their patients and be able to [bill] for and receive reimbursement for across all of their patients. If it's a pure play, and it's going through either benefit, then the adoption issues become more clear, given that kind of framework. What becomes even more complicated is when there's both pharmacy benefit coverage and adjudication and medical benefit coverage and adjudication. So, you have both to contend with.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Dr Joseph Alvarnas Highlights the Current State of the Oncology Biosimilar Market
November 9th 2022Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope, explains what the recent FDA approvals of Stimufend and Vegzelma, 2 oncology biosimilars, says about the current state of the oncology biosimilar space.
Expert Opinion: What Factors Will Have the Greatest Impact on US Adoption of Humira Biosimilars?
April 12th 2022Jeffrey Casberg, vice president of pharmacy at IPD Analytics, weighs in on the factors he thinks will most affect market share among adalimumab biosimilars when they enter the US market in 2023.
